PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32464004-8	2019	Also, the IHC expression patterns of CD133 and CD44, known to associate CSCs, showed differential changes depending on the end-point stage of carcinogenesis and celecoxib treatment.	Celecoxib	161-170	prominin 1	Mus musculus	37-42	
35115900-12	2022	Celecoxib treatment of mice significantly suppressed tumor CD133 expression to 67.5 +- 7.8% of controls (P < 0.005) and reduced tumor 89Zr-CD133 IgG uptake from 15.5 +- 1.4% at baseline to 12.3 +- 2.0%ID/g (P < 0.01).	Celecoxib	0-9	prominin 1	Mus musculus	59-64	
35115900-12	2022	Celecoxib treatment of mice significantly suppressed tumor CD133 expression to 67.5 +- 7.8% of controls (P < 0.005) and reduced tumor 89Zr-CD133 IgG uptake from 15.5 +- 1.4% at baseline to 12.3 +- 2.0%ID/g (P < 0.01).	Celecoxib	0-9	prominin 1	Mus musculus	139-144	
21054139-6	2011	The aim of the present study was to investigate the role of celecoxib, a selective COX-2 inhibitor, in enhancing the therapeutic effects of radiation on CD133(+) glioblastomas.	Celecoxib	60-69	prominin 1	Mus musculus	153-158	
21054139-7	2011	METHODS: Cells positive for CD133 were isolated from glioblastoma specimens and characterized by flow cytometry, then treated with celecoxib and/or ionizing radiation (IR).	Celecoxib	131-140	prominin 1	Mus musculus	28-33	
21054139-8	2011	Clonogenic assay, cell irradiation, cell cycle analysis, Western blot, and xenotransplantation were used to assess the effects of celecoxib alone, IR alone, and IR with celecoxib on CD133(+) and CD133(-) glioblastoma cells.	Celecoxib	169-178	prominin 1	Mus musculus	182-187	
21054139-12	2011	The authors further demonstrated that 30 muM celecoxib was able to effectively enhance the IR effect in inhibiting colony formation and increasing IR-mediated apoptosis in celecoxib-treated CD133(+) glioblastoma cells.	Celecoxib	45-54	prominin 1	Mus musculus	190-195	
21054139-12	2011	The authors further demonstrated that 30 muM celecoxib was able to effectively enhance the IR effect in inhibiting colony formation and increasing IR-mediated apoptosis in celecoxib-treated CD133(+) glioblastoma cells.	Celecoxib	172-181	prominin 1	Mus musculus	190-195	
21054139-14	2011	In vivo xenotransplant analysis further confirmed that CD133(+)-associated tumorigenicity was significantly suppressed by celecoxib treatment.	Celecoxib	122-131	prominin 1	Mus musculus	55-60	
21054139-15	2011	Importantly, pretreatment of CD133(+) glioblastoma cells with a combination of celecoxib and IR before injection into the striatum of SCID mice resulted in a statistically significant reduction in tumor growth and a statistically significant increase in the mean survival rate of the mice.	Celecoxib	79-88	prominin 1	Mus musculus	29-34	
21054139-16	2011	CONCLUSIONS: Celecoxib combined with radiation plays a critical role in the suppression of growth of CD133(+) glioblastoma stemlike cells.	Celecoxib	13-22	prominin 1	Mus musculus	101-106	
20526717-11	2010	Notably, xenotransplantation analysis demonstrated that the treatment of celecoxib could further suppress the expressions of angiogenic and stemness-related genes in treated MB-CD133(+) grafts of SCID mice.	Celecoxib	73-82	prominin 1	Mus musculus	177-182